
Welcome to Episode #6 of NAF This Week!
Join National Ataxia Foundation CEO Andrew Rosen for a quick look at what’s happening across NAF and the Ataxia community — from research and advocacy to programs, events, and more.
In this episode: This week, Andrew discusses recent FDA developments and what a new rare disease framework could mean for the Ataxia community. He highlights the importance of patient engagement, outside expertise, and a more predictable drug development process, along with opportunities for the community to learn more and get involved.
Links & Resources Mentioned:
🔗 Rare Disease Framework Public Meeting – October 28: www.reaganudall.org/news-and-events/events/rare-disease-framework-public-meeting
🔗 FDA White Paper – A New Framework for Rare Disease Review: www.fda.gov/media/195694/download?attachment
🔗 Information about SARA Scores: www.ataxia.org/scasourceposts/snapshot-what-is-the-f-sara
Stay Connected with NAF: Visit www.ataxia.org to learn more about Ataxia, find resources and support, get involved, and follow the latest progress in Ataxia research.
More episodes from "NAF This Week"



Don't miss an episode of “NAF This Week” and subscribe to it in the GetPodcast app.







